/
JAGX
$2.96-$0.05 (-1.66%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.5M
6M shares
52-week range
$2.12 – $88.77
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
63.06%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-16967033.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Cost of revenue | $2.8M | $3.8M | $3.3M | $2.3M | $2.0M | $2.0M | $2.0M | $3.8M |
| Gross profit | $1.7M | $2.0M | $6.1M | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M |
| Gross margin | 37.4% | 33.9% | 65.1% | 46.2% | 83.1% | 79.1% | 83.3% | 67.2% |
| R&D | $5.2M | $5.8M | $6.4M | $15.1M | $17.6M | $18.6M | $16.5M | $25.0M |
| Operating income | −$30.8M | −$28.9M | −$26.6M | −$40.7M | −$34.4M | −$34.3M | −$30.8M | −$45.9M |
| EBITDA | −$27.8M | −$30.9M | −$28.7M | −$42.4M | −$33.4M | −$32.8M | −$36.7M | −$37.9M |
| Net income | −$32.1M | −$38.5M | −$33.8M | −$52.6M | −$47.5M | −$41.3M | −$38.5M | −$53.6M |
| Net margin | -727.9% | -667.3% | -360.2% | -1213.3% | -396.9% | -423.1% | -329.3% | -465.4% |
| EPS (diluted) | -1810550318.00 | -106403456.00 | -11814153.00 | -4631759.00 | -1899528.00 | -93992.00 | -4574.07 | -803.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-4.20 | $-4.20–$-4.20 | 1 |
| 2027 | $4M | $-9.45 | $-9.45–$-9.45 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Jaguar Health, Inc.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
www.jaguar.health- Employees
- 47
- IPO / List date
- May 13, 2015
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds JAGX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in JAGX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-30 | 1-for-35reverse |
| 2026-03-02 | 1.1-for-1 |
| 2025-03-24 | 1-for-25reverse |
| 2024-05-23 | 1-for-60reverse |
| 2023-01-23 | 1-for-75reverse |
Recent trades on TradeandTell
No one on the platform has traded JAGX yet.
